These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 33433931)

  • 21. Anti-A and anti-B: what are they and where do they come from?
    Branch DR
    Transfusion; 2015 Jul; 55 Suppl 2():S74-9. PubMed ID: 26174901
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Isoagglutinin-reduced immunoglobulin retains efficacy in mouse models of immune thrombocytopenia and rheumatoid arthritis and is less likely to cause intravenous immunoglobulin-associated hemolysis.
    Cen SY; Branch DR
    Transfusion; 2020 Feb; 60(2):250-255. PubMed ID: 31837028
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Hemolytic transfusion reactions after administration of intravenous immune (gamma) globulin: a case series analysis.
    Daw Z; Padmore R; Neurath D; Cober N; Tokessy M; Desjardins D; Olberg B; Tinmouth A; Giulivi A
    Transfusion; 2008 Aug; 48(8):1598-601. PubMed ID: 18466176
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Hemolytic events after the administration of lyophilized versus liquid immune globulin: an analysis of a single manufacturer's safety database.
    Berg R; Jacob D; Fuellenhals E
    Transfusion; 2015 Aug; 55(8):1847-54. PubMed ID: 25867204
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Hemolytic adverse effects of intravenous immunoglobulin: modeling predicts risk reduction with anti-A/B immunoaffinity chromatography and to a lesser extent with anti-A donor screening.
    Mallick R; Hubsch A; Barnes DG
    Transfusion; 2018 Dec; 58(12):2752-2756. PubMed ID: 30284263
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Treatment-associated hemolysis in Kawasaki disease: association with blood-group antibody titers in IVIG products.
    Bruggeman CW; Nagelkerke SQ; Lau W; Manlhiot C; de Haas M; van Bruggen R; McCrindle BW; Yeung RSM; Kuijpers TW
    Blood Adv; 2020 Jul; 4(14):3416-3426. PubMed ID: 32722782
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Haemolysis after treatment with intravenous immunoglobulin due to anti-A.
    Morgan S; Sorensen P; Vercellotti G; Zantek ND
    Transfus Med; 2011 Aug; 21(4):267-70. PubMed ID: 21605202
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Early intravenous immunoglobulin replacement in hypogammaglobulinemic heart transplant recipients: results of a clinical trial.
    Sarmiento E; Diez P; Arraya M; Jaramillo M; Calahorra L; Fernandez-Yañez J; Palomo J; Sousa I; Hortal J; Barrio J; Alonso R; Muñoz P; Navarro J; Vicario J; Fernandez-Cruz E; Carbone J
    Transpl Infect Dis; 2016 Dec; 18(6):832-843. PubMed ID: 27639067
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Intravenous immunoglobulin G use and pharmacovigilance in a tertiary care children's hospital.
    Yori S; Belleri F; Testard J; Fierro Vidal Á; Rousseau M
    Arch Argent Pediatr; 2021 Jun; 119(3):192-197. PubMed ID: 34033419
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Mechanism of therapeutic effect of high-dose intravenous immunoglobulin. Attenuation of acute, complement-dependent immune damage in a guinea pig model.
    Basta M; Kirshbom P; Frank MM; Fries LF
    J Clin Invest; 1989 Dec; 84(6):1974-81. PubMed ID: 2687331
    [TBL] [Abstract][Full Text] [Related]  

  • 31. High-dose intravenous immunoglobulin is strongly associated with hemolytic anemia in patients with Kawasaki disease.
    Nolan BE; Wang Y; Pary PP; Luban NLC; Wong ECC; Ronis T
    Transfusion; 2018 Nov; 58(11):2564-2571. PubMed ID: 30265742
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Do immune complexes play a role in hemolytic sequelae of intravenous immune globulin?
    Zimring JC
    Transfusion; 2015 Jul; 55 Suppl 2():S86-9. PubMed ID: 26174903
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Intravenous immune globulin therapy for Stevens-Johnson syndrome/toxic epidermal necrolysis complicated by hemolysis leading to pigment nephropathy and hemodialysis.
    Ririe MR; Blaylock RC; Morris SE; Jung JY
    J Am Acad Dermatol; 2013 Aug; 69(2):221-5. PubMed ID: 23673282
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Intravenously applied IgG stimulates complement attenuation in a complement-dependent autoimmune disease at the amplifying C3 convertase level.
    Lutz HU; Stammler P; Bianchi V; Trüeb RM; Hunziker T; Burger R; Jelezarova E; Späth PJ
    Blood; 2004 Jan; 103(2):465-72. PubMed ID: 14512320
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Transient neonatal liver disease after maternal antenatal intravenous Ig infusions in gestational alloimmune liver disease associated with neonatal haemochromatosis.
    Baruteau J; Heissat S; Broué P; Collardeau-Frachon S; Bouvier R; Fabre M; Debiec H; Ronco P; Uzan M; Narcy P; Cordier MP; Lachaux A; Lamireau T; Elleau C; Filet JP; Mitanchez D; Dupuy MP; Salaün JF; Odent S; Davison J; Debray D; Guigonis V
    J Pediatr Gastroenterol Nutr; 2014 Nov; 59(5):629-35. PubMed ID: 25079484
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Adverse reactions and influencing factors in children with primary immunodeficiencies receiving intravenous immunglobulin replacement.
    Ibis IBP; Erdur B; Erdem SB; Karaman S; Gulez N; Genel F
    Allergol Immunopathol (Madr); 2020; 48(6):738-744. PubMed ID: 32703652
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A retrospective analysis of haemolytic reactions to intravenous immunoglobulin using data from the Transfusion-Transmitted Injuries Surveillance System (Ontario).
    Batarfi K; Liu Y; Nixon J; Webert KE; John MS; Karunakaran M; Alhomsi N; Park JJ; Heddle NM
    Vox Sang; 2023 Sep; 118(9):753-762. PubMed ID: 37592865
    [TBL] [Abstract][Full Text] [Related]  

  • 38. High-dose intravenous immunoglobulin treatment activates complement in vivo.
    Mollnes TE; Høgåsen K; De Carolis C; Vaquero E; Nielsen EW; Fontana L; Perricone R
    Scand J Immunol; 1998 Sep; 48(3):312-7. PubMed ID: 9743219
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Hemolytic anemia following high dose intravenous immunoglobulin in patients with chronic neurological disorders.
    Markvardsen LH; Christiansen I; Harbo T; Jakobsen J
    Eur J Neurol; 2014; 21(1):147-52. PubMed ID: 24180709
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Donor screening reduces the isoagglutinin titer in immunoglobulin products.
    Siani B; Willimann K; Wymann S; Marques Antunes A; Widmer E
    Transfusion; 2015 Jul; 55 Suppl 2():S95-7. PubMed ID: 26174905
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.